Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$565 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
8.2
Industry P/E
--
EV/EBITDA
0.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.7
Face value
--
Shares outstanding
69,234,096
CFO
$-357.08 Mln
EBITDA
$-396.66 Mln
Net Profit
$-434.90 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Regulus Therapeutics (RGLS)
| 416.5 | 3.4 | 466.7 | 298.0 | 50.2 | 0.0 | -39.4 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|
|
Regulus Therapeutics (RGLS)
| 23.2 | -6.6 | -76.3 | 51.7 | -4.4 | -92.4 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting... miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was formerly known as Regulus Therapeutics LLC and changed its name to Regulus Therapeutics Inc. in January 2009. The company was incorporated in 2007 and is based in San Diego, California. As of June 25, 2025, Regulus Therapeutics Inc. operates as a subsidiary of Novartis AG. Read more
CEO & Director
Mr. Joseph P. Hagan M.B.A.
CEO & Director
Mr. Joseph P. Hagan M.B.A.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Regulus Therapeutics Inc (RGLS) is $8.16 (NASDAQ) as of 25-Jun-2025 09:30 EDT. Regulus Therapeutics Inc (RGLS) has given a return of 50.24% in the last 3 years.
Since, TTM earnings of Regulus Therapeutics Inc (RGLS) is negative, P/E ratio is not available.
The P/B ratio of Regulus Therapeutics Inc (RGLS) is 8.19 times as on 25-Jun-2025, a 108 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-2.23
|
1.35
|
|
2023
|
-0.86
|
1.22
|
|
2022
|
-0.81
|
0.69
|
|
2021
|
-0.12
|
0.06
|
|
2020
|
-0.42
|
0.25
|
The 52-week high and low of Regulus Therapeutics Inc (RGLS) are Rs 8.35 and Rs 0.83 as of 03-Apr-2026.
Regulus Therapeutics Inc (RGLS) has a market capitalisation of $ 565 Mln as on 25-Jun-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Regulus Therapeutics Inc (RGLS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.